Placebo + Sevelamer Carbonate (GZ419831)

Phase 3Completed
0 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyperphosphatemia

Conditions

Hyperphosphatemia

Trial Timeline

Jun 7, 2017 → Aug 16, 2019

About Placebo + Sevelamer Carbonate (GZ419831)

Placebo + Sevelamer Carbonate (GZ419831) is a phase 3 stage product being developed by Sanofi for Hyperphosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03001011. Target conditions include Hyperphosphatemia.

What happened to similar drugs?

2 of 14 similar drugs in Hyperphosphatemia were approved

Approved (2) Terminated (0) Active (12)
🔄KHK7791 + PlaceboKyowa KirinPhase 3
🔄KHK7791 + PlaceboKyowa KirinPhase 3
🔄KHK7791Kyowa KirinPhase 3
🔄KHK7791Kyowa KirinPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03001011Phase 3Completed

Competing Products

20 competing products in Hyperphosphatemia

See all competitors
ProductCompanyStageHype Score
EOS789 + Placebo + RenvelaChugai PharmaceuticalPhase 1
29
DS-2330b PIB + Placebo + Sevelamer + DS-2330b TabletDaiichi SankyoPhase 1
29
ASP1585 + Placebo + Sevelamer hydrochlorideAstellas PharmaPhase 2
35
ASP1585Astellas PharmaPhase 2
35
the standard-dose group (4 g/day)Kyowa KirinPre-clinical
33
KHK7791 + PlacebpKyowa KirinPhase 2
35
KHK7791Kyowa KirinPhase 2
35
KHK7791 + PlaceboKyowa KirinPhase 3
40
the low-dose group (1.5 g/day) or the standard-dose group (4 g/day)Kyowa KirinPre-clinical
33
KHK7791 + PlaceboKyowa KirinPhase 3
40
KHK7791Kyowa KirinPhase 3
40
KHK7791 + PlaceboKyowa KirinPhase 2
35
KHK7791Kyowa KirinPhase 3
40
SBR759 + Sevelamer HCl + SBR759 + Sevelamer HClNovartisPhase 2
35
SBR759A + SBR759A + SBR759A + SBR759A + SBR759ANovartisPhase 3
40
PA21Kissei PharmaceuticalPhase 3
40
Placebo + Sevelamer carbonateSanofiPhase 2
35
Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tabletBayerPre-clinical
23
Lanthanum Carbonate (Fosrenol, BAY77-1931)BayerPre-clinical
23
Lanthanum Carbonate (BAY77-1931)BayerPhase 2
32